Boston Scientific Corp (BSX)vsPerspective Therapeutics Inc. (CATX)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
CATX
Perspective Therapeutics Inc.
$4.29
+1.18%
HEALTHCARE · Cap: $507.00M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 2270714% more annual revenue ($20.07B vs $884,000). BSX leads profitability with a 14.4% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
CATX
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Intrinsic value data unavailable for CATX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -41.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : CATX
The strongest argument for CATX centers on Debt/Equity, Altman Z-Score, Price/Book.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : CATX
The primary concerns for CATX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
BSX profiles as a growth stock while CATX is a value play — different risk/reward profiles.
CATX carries more volatility with a beta of 1.80 — expect wider price swings.
BSX is growing revenue faster at 15.9% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 24/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Perspective Therapeutics Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Perspective Therapeutics Inc. is an innovative biotechnology company specializing in the development of next-generation radiopharmaceuticals designed to treat various types of cancer. Utilizing cutting-edge radioisotope technologies, the company aims to enhance the efficacy of cancer treatments, thereby improving patient outcomes in a rapidly evolving market for targeted therapies. With a strong leadership team and strategic partnerships, Perspective Therapeutics is well-equipped to advance its mission and deliver breakthrough solutions that address the growing need for effective cancer interventions.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?